24-NHL-37-RG (R1979-ONC-2105): A Phase 3, Open Label, Randomized Study Comparing The Efficacy and Safety of Odronextamab (Regn1979), An Anti-Cd20 ? Anti-Cd3 Bispecific Antibody, in Combination With Chop (O-Chop) Versus Rituximab in Combination With Chop (

Grants and Contracts Details

StatusActive
Effective start/end date6/14/24 → 6/14/26

Funding

  • Regeneron Pharmaceuticals: $2.00